Figure 8
From: Olig2 regulates p53-mediated apoptosis, migration and invasion of melanoma cells
Combinational effects of Olig2 silencing and BRAF inhibitor (dabrafenib) or MEK inhibitor (trametinib) on melanoma cells. (a, b) A375 and 501mel cells were incubated with CRISPR-Olig2, dabrafenib (50 nM), trametinib (5 nM), or their combinations for 24 h. Ratio of phospho-ERK/total ERK and Olig2 (H-10)/β-actin were indicated below each lane and obtained by densitometry using the ImageJ software. Original images of blots were provided in supplementary file. Viability of A375 (c) and 501mel (d) was determined by EZ-Cytox assay 48 h and 72 h after treatment respectively. Results are presented as percentages of the Con and the data were analyzed using Student's unpaired t-tests (*p < 0.05; **p < 0.01; ***p < 0.001, n = 3).
